NANJING, China, July 23, 2024 /PRNewswire/ — Tuniu Corporation (NASDAQ:TOUR) ("Tuniu" or the "Company"), a leading online leisure travel company in China, today announced that it plans to release its unaudited financial results for the second quarter ended June 30, 2024, before the market opens on August 6, 2024.

Tuniu’s management will hold an earnings conference call at 8:00 am U.S. Eastern Time on August 6, 2024 (8:00 pm Beijing/Hong Kong Time on August 6, 2024).

Listeners may access the call by dialing the following numbers:

US

1-888-346-8982

Hong Kong

852-301-84992

Mainland China

4001-201203

International

1-412-902-4272

Conference ID: Tuniu 2Q 2024 Earnings Conference Call            

A telephone replay will be available one hour after the end of the conference call through August 13, 2024. The dial-in details are as follows:

US

1-877-344-7529

International

1-412-317-0088

Replay Access Code: 9667429

Additionally, a live and archived webcast of this conference call will be available at http://ir.tuniu.com/.

About Tuniu Corporation

Tuniu (Nasdaq:TOUR) is a leading online leisure travel company in China that offers integrated travel service with a large selection of packaged tours, including organized and self-guided tours, as well as travel-related services for leisure travelers through its website tuniu.com and mobile platform. Tuniu provides one-stop leisure travel solutions and a compelling customer experience through its online platform and offline service network, including a dedicated team of professional customer service representatives, 24/7 call centers, extensive networks of offline retail stores and self-operated local tour operators. For more information, please visit http://ir.tuniu.com.

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

PeproMene Bio, Inc. Announces Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) in the Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope

IRVINE, Calif., Jan. 18, 2024 /PRNewswire/ — PeproMene Bio, Inc., a clinical-stage…

HawkEye 360 Strengthens Strategic Presence in Japan with the Appointment of Hiroshi Ogawa

Seasoned Aerospace Executive To Lead Regional Operations And Strengthen National Security Partnerships…

The Future is ALL ON: CES 2024 Opens, Showcasing the Latest Innovations in AI, Sustainability and Mobility

LAS VEGAS, Jan. 10, 2024 /PRNewswire/ — CES® 2024 opened today showing it…